American Regent v. BPI Labs: Selenium Injection Patents Dismissed in 18 Days
American Regent, Inc. asserted two patents covering selenious acid selenium injection formulations against BPI Labs, LLC in Florida Middle District Court. The plaintiff voluntarily dismissed its infringement claims without prejudice just 18 days after filing — one of the shortest active windows seen in pharmaceutical patent enforcement actions.
A rapid voluntary exit: American Regent’s 18-day selenium patent action
On June 6, 2025, American Regent, Inc. — a pharmaceutical company and holder of patents covering selenious acid injectable selenium products — filed an infringement action against BPI Labs, LLC in the United States District Court for the Middle District of Florida. The asserted patents, US12150957B2 and US11998565B2, relate to selenious acid formulations delivering selenium by injection, specifically at the concentrations found in the accused BPI Labs products.
The case closed on June 24, 2025, just 18 days after filing, when American Regent voluntarily dismissed its claims against BPI Labs without prejudice. A dismissal without prejudice means no final adjudication on the merits occurred: American Regent retains the legal right to reassert the same claims in a future action, subject to applicable statutes of limitations and any applicable filing bars. BPI Labs faces no res judicata bar from this termination.
The speed of resolution — 18 days — is consistent with an early negotiated resolution, a licensing discussion that mooted the litigation, or a strategic decision to refile in a different forum. The public record is silent on settlement terms or any agreement between the parties. No defendant counsel of record was filed, suggesting BPI Labs may not have formally appeared before dismissal, which itself may have influenced the plaintiff’s calculus.
Filing to Dismissed without Prejudice in 18 days
18-day lifespan — well below the median district court patent case duration of 2+ years
Dismissed without prejudice: what this ruling means for both parties
Without prejudice: no merits ruling, claims can return
A voluntary dismissal without prejudice under Federal Rule of Civil Procedure 41(a) terminates the current action but does not resolve the underlying dispute on its merits. American Regent retains the right to bring identical or substantially similar claims against BPI Labs in the future. No court finding regarding infringement, validity, or claim scope was made in this proceeding.
Rule 41(a) — no merits adjudicationAmerican Regent preserves all enforcement options
By dismissing without prejudice, American Regent keeps its patent enforcement strategy intact. It may refile in Florida, in another district, or pursue alternative routes such as an ITC Section 337 complaint. The dismissal also suggests the plaintiff may be monitoring BPI Labs’ product pipeline or awaiting a stronger evidentiary record before proceeding.
Refiling right preservedBPI Labs faces no judgment — but uncertainty persists
BPI Labs escapes this action without a finding of infringement or any injunction. However, the dismissal without prejudice provides no declaratory relief or validity ruling. BPI Labs remains exposed to future enforcement on the same patents and cannot rely on this termination as a shield. The absence of defendant counsel of record suggests the dispute may have resolved before formal engagement.
No res judicata protectionSelenium injectable market remains under IP pressure
The rapid filing-and-dismissal pattern is consistent with litigation used as a market signalling or negotiating tool in the specialty injectable pharmaceutical sector. Competitors producing selenious acid formulations at similar concentrations should treat this action as a signal that American Regent is actively monitoring the space. The two asserted patents remain fully enforceable and commercially live.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Pharmaceutical company — holder of US12150957B2 and US11998565B2 (selenious acid injections)Search in Eureka ↗ |
| Defendant | BPI Labs, LLC | Company | BPI Labs, LLC — manufacturer of selenious acid selenium injection productsSearch in Eureka ↗ |
| Plaintiff counsel | Christina Dashe | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert Troy Smith | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Ryan Elizabeth Conkin | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Uma Everett | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Bedell, Dittmar, DeVault, Pillans & Coxe, P.A. | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Kessler, Goldstein & Fox p.l.l.c | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox P.L.L.C | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Florida Middle District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice is unambiguous in its scope: American Regent dismissed ‘its claim against Defendant BPI Labs, LLC without prejudice,’ covering the entire action in a single filing. The phrasing ‘its claim’ — used in the singular — may reflect the unified nature of the infringement cause of action across both asserted patents rather than indicating only one patent was dismissed. No conditions, carve-outs, or cross-claims are mentioned, and no consideration or settlement terms appear in the public record. The without-prejudice designation is controlling: BPI Labs cannot invoke this dismissal as a defence to future infringement claims on US12150957B2 or US11998565B2.
US12150957B2 & US11998565B2 — Selenious Acid Selenium Injection Formulations
US12150957B2 and US11998565B2 both cover selenious acid-based injectable selenium products used primarily as trace element supplements in parenteral nutrition. The asserted products span three concentration formats — 12 mcg/2 mL, 60 mcg/mL, and 600 mcg/10 mL — indicating the patents likely protect formulation compositions, manufacturing processes, or dosage configurations rather than the selenium compound itself, which is a long-known micronutrient. The application numbers (US18/672876 and US18/124391) suggest relatively recent prosecution, consistent with product life-cycle IP strategies in specialty injectables.
In the specialty injectable pharmaceutical market, selenium formulations occupy a niche but commercially important segment of the parenteral nutrition supply chain, particularly in critical care and oncology settings. American Regent’s decision to pursue patent protection across multiple concentration SKUs and then immediately enforce against a competitor suggests these patents form a core defensive perimeter around a profitable product line. Any manufacturer, compounder, or 503B outsourcing facility producing selenious acid injectables at these concentrations should treat these patents as live enforcement assets.
Should you run an FTO analysis against US12150957B2 and US11998565B2?
If your organisation manufactures, compounds, distributes, or sources selenious acid selenium injectable products — particularly at concentrations of 6 mcg/mL, 60 mcg/mL, or in 2 mL, 1 mL, or 10 mL vial formats — both patents asserted in this case warrant a freedom-to-operate review. The dismissal without prejudice means American Regent can refile at any time, and the absence of any invalidity or non-infringement ruling provides no safe harbour.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US12150957B2 and US11998565B2 against your specific formulation parameters, concentration ranges, and manufacturing methods. Eureka surfaces prior art, identifies prosecution history disclaimers, and flags design-around opportunities — giving your R&D and legal teams a defensible FTO position before American Regent’s next enforcement move.
Run a freedom-to-operate analysis on US12150957B2 to assess your product’s exposure
Run FTO in Eureka →Similar selenium and injectable pharmaceutical patent cases in US district courts
Explore related infringement actions involving injectable pharmaceutical formulation patents filed in Florida and other US district courts, with comparable rapid-resolution outcomes.
What this case signals for the selenium injectable pharma IP landscape
An 18-day lifecycle and no defendant appearance suggests this action functioned as leverage rather than litigation.
Ultra-short patent actions often signal licensing talks or forum strategy
When a patent plaintiff dismisses without prejudice before the defendant even files counsel, it typically signals one of three things: a licensing agreement was reached quickly, the plaintiff is repositioning to a different forum, or the filing served as commercial leverage. All three scenarios leave the asserted patents — US12150957B2 and US11998565B2 — fully live for future enforcement.
No defendant counsel filed: a rare procedural signal worth noting
The absence of any recorded defendant counsel in an 18-day action is atypical and commercially meaningful. It suggests BPI Labs either resolved the matter through direct negotiation prior to formal engagement or was not yet served. IP professionals monitoring selenium injectable competitors should track whether BPI Labs modifies product labelling or concentrations following this action.
American v BPI — key questions answered
American Regent asserted US12150957B2 (application US18/672876) and US11998565B2 (application US18/124391) — both covering selenious acid injectable selenium formulations. The accused products were three BPI Labs selenious acid products at concentrations of 6 mcg/mL, 60 mcg/mL, and a 10 mL 60 mcg/mL format.
Dismissal without prejudice means no court made a finding on infringement or patent validity. BPI Labs is not protected by res judicata and faces the same legal exposure as before the case was filed. American Regent retains the right to refile identical claims against BPI Labs in the future, subject only to applicable statutes of limitations.
The public record does not disclose the reason. However, an 18-day lifecycle before any defendant appearance is consistent with: (1) a negotiated licence or commercial resolution reached outside court; (2) a strategic decision to refile in a different venue; or (3) the filing serving as leverage that achieved its objective. No settlement terms are publicly available.
Yes. Both patents remain fully enforceable. The voluntary dismissal without prejudice has no effect on the validity, claim scope, or enforceability of either patent. No court ruled on any infringement or invalidity question. American Regent may assert these patents against BPI Labs or any other party at any time.
The case was filed in the United States District Court for the Middle District of Florida (case no. 8:25-cv-01470). No defendant counsel appeared and no venue challenge was filed before the voluntary dismissal, so the public record does not reveal why this district was selected. Florida Middle District is an active venue for pharmaceutical and specialty product IP disputes.
PatSnap Eureka searches patents and litigation data to answer instantly.